CF
PBM icon

Cantor Fitzgerald’s Psyence Biomedical PBM Stock Holding History

Cantor Fitzgerald’s Portfolio PBM Stock Details PBM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-90
Closed -$33.7K – 346
2024
Q3 		$33.7K Hold
90
– – ﹤0.01% 170
2024
Q2 		$101K Hold
90
– – 0.02% 164
2024
Q1 		$371K Buy
+90
New +$375K 0.09% 108

Other funds holding PBM

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
EP
Essential Planning Portsmouth, New Hampshire $315M AUM 11.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Cantor Fitzgerald's PBM Position: Q4 2024 in Review

Cantor Fitzgerald sold out of Psyence Biomedical (PBM) in Q4 2024, closing a stake of 90 shares — an estimated $33.7K sold.

Cantor Fitzgerald first reported a position in PBM in Q1 2024 and held it in 3 quarters. The position peaked at $371K in Q1 2024. 11 funds tracked by Wall St. Rank hold PBM as of Q4 2024.

  • Cantor Fitzgerald reported no remaining Psyence Biomedical position as of Q4 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 90 Psyence Biomedical shares in Q4 2024, an estimated $33.7K.
  • Cantor Fitzgerald first reported a position in Psyence Biomedical in Q1 2024 and held it in 3 quarters.
  • Cantor Fitzgerald's Psyence Biomedical position peaked at $371K in Q1 2024.
  • 11 funds tracked by Wall St. Rank held Psyence Biomedical as of Q4 2024.

Based on Cantor Fitzgerald's 13F filing for Q4 2024, filed 14 Feb 2025.